Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.Hematol Am Soc Hematol Educ Program. 2015; 2015: 294-298
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood. 2016; 127: 2391-2405
- Myelodysplastic syndromes/neoplasms, overview.in: Swerdlow S.H. Campo E. Harris N.L. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon (France)2008: 88-93
- Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.J Clin Pathol. 1987; 40: 652-656
- Myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry.Leuk Lymphoma. 1995; 20: 17-25
- A quantitative evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow cytometry.Leuk Res. 1993; 17: 839-846
- Complement receptor type 1 (CR1) deficiency on neutrophils in myelodysplastic syndrome.Br J Haematol. 1994; 88: 409-412
- DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).Br J Haematol. 1986; 62: 239-245
- Flow cytometric evaluation of proliferative activity and ploidy in myelodysplastic syndromes and acute leukemias.Basic Appl Histochem. 1986; 30: 181-192
- Myeloid cell surface phenotype in myelodysplasia: evidence for abnormal persistence of an early myeloid differentiation antigen.Am J Hematol. 1986; 22: 251-257
- Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia.Am J Clin Pathol. 2005; 124: 170-181
- Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders.Am J Clin Pathol. 2003; 120: 854-865
- Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.Blood. 2002; 100: 3887-3896
- Clinical implications of blast immunophenotypes in myelodysplastic syndromes.Leuk Lymphoma. 2005; 46: 1269-1274
- Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia.Leuk Res. 2000; 24: 359-366
- Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common.Am J Clin Pathol. 2006; 125: 884-894
- Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.Blood. 2001; 98: 979-987
- Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.Haematologica. 2009; 94: 1066-1074
- Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.Leukemia. 2014; 28: 1793-1798
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.Haematologica. 2009; 94: 1124-1134
- Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.Leukemia. 2012; 26: 1730-1741
- Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.Cytometry B Clin Cytom. 2014; 86: 207-215
- Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.Blood. 2010; 115: 1779-1784
- Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.Cytometry B Clin Cytom. 2013; 84: 157-166
- Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination.Cytometry B Clin Cytom. 2009; 76: 18-26
- Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.Cytometry B Clin Cytom. 2009; 76: 27-36
- Application of flow cytometry for myelodysplastic syndromes: pitfalls and technical considerations.Cytometry B Clin Cytom. 2016; 90: 358-367
- Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.Eur J Haematol. 2011; 87: 409-418
- Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms.Am J Clin Pathol. 2014; 142: 292-298
- Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.Am J Clin Pathol. 2008; 129: 300-308
- The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.Leukemia. 2008; 22: 1175-1183
- Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.Blood. 2008; 111: 1067-1077
- Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry.Blood. 2001; 98: 2498-2507
- Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.Haematologica. 2012; 97: 1209-1217
- High-sensitivity detection of PNH Red blood cells, red cell precursors, and white blood cells.Curr Protoc Cytom. 2015; 72: 6.37.1-30
- Immunophenotypes of chronic myelomonocytic leukemia (CMML) subtypes by flow cytometry: a comparison of CMML-1 vs CMML-2, myeloproliferative vs dysplastic, De Novo vs therapy-related, and CMML-specific cytogenetic risk subtypes.Am J Clin Pathol. 2016; 146: 170-181
- Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression.Am J Clin Pathol. 2013; 140: 686-692
- Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.Blood. 2015; 125: 3618-3626
- An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Haematologica. 2015; 100: 1117-1130
- Assessment of erythroid dysplasia by “difference from normal” in routine clinical flow cytometry workup.Cytometry B Clin Cytom. 2015; 88: 125-135
- Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.Leukemia. 2013; 27: 1981-1987
- Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.Haematologica. 2017; 102: 308-319
- Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.Am J Clin Pathol. 2012; 138: 732-743
- Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.Haematologica. 2009; 94: 1160-1163
- Immunophenotypic clustering of myelodysplastic syndromes.Blood. 2002; 100: 2349-2356
- Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria.Cytometry B Clin Cytom. 2013; 84: 315-323
- The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders.Am J Clin Pathol. 2010; 134: 749-761
- The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study.Leuk Res. 2009; 33: 1039-1046
- Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.Haematologica. 2017; 102: 320-326
- Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls.Leuk Res. 2008; 32: 215-224
- Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes.Blood. 2006; 108: 1037-1044
- Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes.Leuk Res. 2008; 32: 699-707
- Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia.Haematologica. 2014; 99: e8-10
- Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.Blood. 2003; 102: 394-403
- Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.Blood. 2008; 112: 2681-2686
- Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.Cancer. 2010; 116: 4549-4563
- Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: a study on 804 patients.Cytometry B Clin Cytom. 2015; 88: 154-164
- Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics.Haematologica. 2013; 98: 201-207
- Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.Cytometry B Clin Cytom. 2013; 84: 194-197
- Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.Eur J Cancer. 2016; 54: 49-56
- The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.Leukemia. 2016; 30: 658-665
- A comparative assessment of flow cytometric scoring systems in MDS, in ASH.Blood. 2014; 124: 5589
- Clinical manifestations and diagnosis of the myelodysplastic syndromes.UpToDate, Waltham (MA)2016 (Version 37.0)
- Diagnostic utility of flow cytometry in myelodysplastic syndromes.Front Oncol. 2016; 6: 161
- High flow cytometric scores identify adverse prognostic subgroups within the revised International Prognostic Scoring System for myelodysplastic syndromes.Br J Haematol. 2014; 167: 100-109
- Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.Cytometry B Clin Cytom. 2010; 78: 154-168
- Revised International Prognostic Scoring System for myelodysplastic syndromes.Blood. 2012; 120: 2454-2465
- Validation of WHO classification-based prognostic scoring system (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for prognosis in myelodysplasia (IWG-PM).Leukemia. 2015; 29: 1502-1513
- Limited flow cytometry panels on bone marrow specimens reduce costs and predict negative cytogenetics.Am J Clin Pathol. 2014; 141: 94-101
- Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.Cytometry B Clin Cytom. 2011; 80: 201-211
Article info
Publication history
Published online: September 20, 2017
Footnotes
Disclosure Statement: The authors have nothing to disclose.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
